Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Phase 2 Terminated 5 enrolled NYU Langone Health National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelSupportive care

Summary

This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy

Timeline

Start: 2013-01
Primary completion: 2015-11
Completion: 2015-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Romiplostim	Peptide	—	Subcutaneous

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Summary

Timeline

Drugs

Indications